source
- Immunotherapy Advances in Upfront SCAC Expose Need for Better Second-Line StrategiesAparna R. Parikh, MD, emphasizes the feasibility of immunotherapy trials in SCAC and the need for better treatment options in the second line and beyond.onclive · 2mo ago↗ source
- Dr Loghavi on the Significance of Updated WHO Diagnostic Criteria for AML in Clinical PracticeSanam Loghavi, MD, discusses updated WHO diagnostic criteria for acute myeloid leukemia and its significance for diagnoses and treatment selection.onclive · 2mo ago↗ source
- FDA Approves Decitabine/Cedazuridine Plus Venetoclax in Newly Diagnosed AMLThe FDA has approved oral decitabine/cedazuridine plus venetoclax for newly diagnosed AML unfit for intensive chemo, based on phase 2 ASCERTAIN-V data.